Zacks Research Has Optimistic Outlook of TEVA Q3 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Stock analysts at Zacks Research increased their Q3 2025 earnings estimates for Teva Pharmaceutical Industries in a research report issued to clients and investors on Monday, November 4th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.67 for the quarter, up from their previous estimate of $0.66. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ FY2025 earnings at $2.55 EPS and Q2 2026 earnings at $0.61 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, November 6th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.04. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.33 billion during the quarter, compared to analyst estimates of $4.08 billion.

A number of other research analysts also recently issued reports on TEVA. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Barclays boosted their price objective on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.67.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $17.50 on Wednesday. The stock’s 50 day moving average is $17.98 and its 200 day moving average is $17.07. Teva Pharmaceutical Industries has a one year low of $8.55 and a one year high of $19.31. The firm has a market cap of $19.83 billion, a P/E ratio of -44.87, a P/E/G ratio of 1.34 and a beta of 0.87. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in TEVA. Allspring Global Investments Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 26.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 36,753 shares of the company’s stock worth $519,000 after purchasing an additional 7,763 shares during the period. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Teva Pharmaceutical Industries by 1.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,159,333 shares of the company’s stock valued at $30,468,000 after purchasing an additional 27,713 shares in the last quarter. Nordea Investment Management AB raised its holdings in Teva Pharmaceutical Industries by 3.0% during the first quarter. Nordea Investment Management AB now owns 91,837 shares of the company’s stock worth $1,299,000 after buying an additional 2,701 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 3.7% in the first quarter. Daiwa Securities Group Inc. now owns 115,693 shares of the company’s stock valued at $1,632,000 after buying an additional 4,170 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $93,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.